迎接新生儿和儿童肺动脉高压的挑战
本文基于第七届世界肺动脉高压研讨会儿科工作组内容,讨论儿童肺动脉高压的进展与挑战。提供更新风险分层工具和治疗算法,涵盖相关心肺疾病策略,并指出缺乏随机对照试验及药物审批难题。
要点
- 更新儿童肺动脉高压风险分层工具和治疗算法,纳入相关心肺疾病策略。
- 治疗仍受限于缺乏随机对照临床试验。
- 强调新生儿肺动脉高压超声心动图判读及团队管理快速变化的生理状态。
核心结论
- 儿童肺动脉高压诊疗取得进展,但随机对照试验缺乏、药物审批和试验设计仍是主要挑战。
研究设计与样本
- 第七届世界肺动脉高压研讨会儿科工作组综述,总结诊断、分类、风险分层和治疗进展并识别知识缺口。
主要发现
- 提供更新风险分层工具和治疗算法,纳入相关心肺疾病患者策略。
- 治疗仍受限于缺乏随机对照临床试验。
- 讨论靶向治疗失败患儿的球囊房间隔造口术、肺移植和Potts分流管理。
- 提出先天性心脏病相关肺动脉高压伴临界肺血管阻力的多模式管理新策略。
- 强调新生儿肺动脉高压超声心动图征象判读及团队管理快速变化生理状态。
关键数值与推荐
- 更新风险分层工具和治疗算法,包括相关心肺疾病策略。
- 讨论球囊房间隔造口术、肺移植和Potts分流用于靶向治疗失败患儿。
- 提出多模式方法管理先天性心脏病相关肺动脉高压伴临界肺血管阻力。
临床怎么用
- 应用更新风险分层工具和治疗算法评估和管理儿童肺动脉高压。
- 对靶向治疗失败患儿考虑球囊房间隔造口术、肺移植或Potts分流。
- 先天性心脏病相关肺动脉高压伴临界肺血管阻力可采用多模式管理策略。
- 新生儿肺动脉高压管理强调超声心动图判读和团队协作应对生理变化。
局限性
- 儿童肺动脉高压治疗缺乏随机对照临床试验。
- 药物审批面临设计准确儿科临床试验的挑战,包括年龄适宜终点和足够入组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Paediatric pulmonary arterial hypertension (PAH) shares common features with adult disease, but is associated with several additional disorders and challenges that require unique approaches. This article discusses recent advances, ongoing challenges and distinct approaches for caring for infants and children with PAH, as presented by the paediatric task force of the 7th World Symposium on Pulmonary Hypertension. We provide updates on diagnosing, classifying, risk-stratifying and treating paediatric pulmonary hypertension (PH) and identify critical knowledge gaps. An updated risk stratification tool and treatment algorithm is provided, now also including strategies for patients with associated cardiopulmonary conditions. Treatment of paediatric PH continues to be hindered by the lack of randomised controlled clinical trials. The challenging management of children failing targeted PAH therapy is discussed, including balloon atrial septostomy, lung transplantation and pulmonary-to-systemic shunt (Potts). A novel strategy using a multimodal approach for the management of PAH associated with congenital heart diseases with borderline pulmonary vascular resistance is included. Advances in diagnosing neonatal PH, especially signs and interpretation of PH by echocardiography, are highlighted. A team approach to the rapidly changing physiology of neonatal PH is emphasised. Challenges in drug approval are discussed, particularly the challenges of designing accurate paediatric clinical trials with age-appropriate end-points and adequate enrolment.
引用
- Ivy D, Rosenzweig EB, Abman SH, et al. Embracing the challenges of neonatal and paediatric pulmonary hypertension. Eur Respir J. 2024. PMID: 39209483. doi:10.1183/13993003.01345-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。